NCT07495852RecruitingPhase 3
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Source: ClinicalTrials.gov · Last updated 30 Mar 2026
Brief summary (registry, in English)
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 510 (estimated)
- First submitted
- 23 Mar 2026
- Start date
- 17 Feb 2026
- Primary completion date
- Jun 2028
- Lead sponsor
- Glaukos Corporation
- Diseases
- Glaucoma, High blood pressure
- NCT number
- NCT07495852
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 510
- From 17 Feb 2026 to the primary completion date, Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior incisional glaucoma surgery in the study eye
- Prior minimally invasive glaucoma (MIGS) surgery in the study eye
Lab values
- Prior argon laser trabeculoplasty (ALT) in the study eye
Who the study is looking for
- Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Dothan | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.